C20 C19 C18
Conditions
Interventions
Group 1: To obtain data concerning systemic release of growth factors and immunogenic factors after radioembolization of hepatic tumors (colorectal cancer).
Sponsors
Klinik und Poliklinik für Radiologie Klinikum der Universität München Campus Großhadern
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: •hepatic metastatic colorectal carcinoma •male/female, 18+ •Indication for radioembolization and HDR-brachytherapy in two sessions •informed consent •chemotherapy break for at least 2 weeks before inclusion •no corticosteroides for at least 2 weeks before inclusion
Exclusion criteria
Exclusion criteria: •life expectancy 70% •chronic infections •ascites •contraindication for angiography, MRI contrast media, X-ray contrast media, MRI and CT •liver cirrhosis •condition after resection of the papilla vateri or DHC stenting •cardio vascular disease (NYHA III/IV) •thrombotic/embolic episodes (stroke) •severe hemorrhages within last 3 month •secondary malignoma within last 5 years •immune suppressive therapy or disease (e.g. condition after organ transplantation, HIV, corticosteroides) •autoimmune disease or inflammatory bowel disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of the amount of tumor infiltrating lymphocytes before and 4-8 weeks after radioembolization of hepatic tumors in not yet treated tumor sites. Determination of the level of systemcally released growth factors after radioembolization of hepatic tumors and correlation with growth tendency of not yet treated tumor parts in the treatment free intervall between radioembolization and brachytherapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| -Analyses of peripheral circulation lymphozytes -Receptorexpression on tumor cells before and after radioembolization | — |
Countries
Germany
Contacts
Public ContactChristel Besseler
Klinik und Poliklinik für Radiologie Klinikum der Universität München Campus Großhadern
Outcome results
None listed